Cancer Control


  • AG013:  A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy
  • A prospective observational study to estimate the incidence of Febrile Neutropenia (FN) among subjects with non-myeloid malignancies at high risk for FN and receiving Neulasta Onpro kit or other physician choice options for prophylaxis of FN

  • For more information, contact Mia Johnson, RN, BSN at 360-788-8240